Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Neuropharmacology
  4. Volume 23, Issue 5
  5. Article
Volume 23, Issue 5
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Background

Worldwide, three million deaths each year are reported due to the harmful use of alcohol. To date, only a few drugs have been approved for the treatment of Alcohol Use Disorder (AUD). This systematic review and meta-analysis aim to assess the long-term efficacy and safety of sodium oxybate (SMO) treatment in patients with AUD.

Methods

We followed the PRISMA statement guidelines and searched PubMed and ISI Web of Science to retrieve the studies of interest. In total, 13 studies on long-term (>12 weeks) SMO administration in patients with AUD were included in this systematic review, and 7 were included in the meta-analysis.

Results

Overall, the abstinence rate after 12 weeks of treatment was similar in the SMO and placebo groups, while it was significantly in favour of SMO compared to Naltrexone (NTX). The completion rate was similar in all three conditions. Mean corpuscular volume (MCV) levels favoured SMO over NTX, while Alcohol Craving Scale (ACS) scores did not favour SMO. The incidence of adverse reactions varied widely between studies.

Conclusion

SMO in the chronic treatment of patients with AUD showed no superiority to placebo in our analysis of published RCTs, although many observational studies reported its beneficial effect in the long term. On the contrary, SMO was superior to NTX treatment on abstinence. The rate of study completion was similar in the three groups. Safety was not an issue in any of the studies included. Further studies are needed to better assess SMO efficacy and safety in the long term.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/1570159X22666240902100058
2024-09-02
2025-03-27

  • From This Site

    /content/journals/cn/10.2174/1570159X22666240902100058
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. RoereckeM. RehmJ. Alcohol use disorders and mortality: A systematic review and meta‐analysis.Addiction201310891562157810.1111/add.1223123627868
     [Google Scholar]
  2. KesslerR.C. ChiuW.T. DemlerO. WaltersE.E. WaltersE.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication.Arch. Gen. Psychiatry200562661762710.1001/archpsyc.62.6.61715939839
     [Google Scholar]
  3. RehmJ. RoomR. van den BrinkW. JacobiF. Alcohol use disorders in EU countries and Norway: An overview of the epidemiology.Eur. Neuropsychopharmacol.200515437738810.1016/j.euroneuro.2005.04.00515925491
     [Google Scholar]
  4. QuigleyJ. Alcohol Use by youth.Pediatrics20191441e2019135610.1542/peds.2019‑135631235610
     [Google Scholar]
  5. RekveD. Global status report on alcohol and health 2018; Poznyak, V.Geneva, SwitzerlandWorld Health Organization2018
     [Google Scholar]
  6. RamalhoR. Alcohol consumption and alcohol-related problems during the COVID-19 pandemic: A narrative review. Australas.Psychiatry Bull R Aust New Zeal Coll Psychiatr2020285524526
     [Google Scholar]
  7. NuttD.J. KingL.A. PhillipsL.D. Drug harms in the UK: A multicriteria decision analysis.Lancet201037697521558156510.1016/S0140‑6736(10)61462‑621036393
     [Google Scholar]
  8. WitkiewitzK. LittenR.Z. LeggioL. Advances in the science and treatment of alcohol use disorder.Sci. Adv.201959eaax404310.1126/sciadv.aax404331579824
     [Google Scholar]
  9. KoobG.F. VolkowN.D. Neurobiology of addiction: A neurocircuitry analysis.Lancet Psychiatry20163876077310.1016/S2215‑0366(16)00104‑827475769
     [Google Scholar]
  10. SoykaM. MüllerC.A. Pharmacotherapy of alcoholism – An update on approved and off-label medications.Expert Opin. Pharmacother.201718121187119910.1080/14656566.2017.134909828658981
     [Google Scholar]
  11. SwiftR.M. AstonE.R. Pharmacotherapy for alcohol use disorder: Current and emerging therapies.Harv. Rev. Psychiatry201523212213310.1097/HRP.000000000000007925747925
     [Google Scholar]
  12. DonoghueK. ElzerbiC. SaundersR. WhittingtonC. PillingS. DrummondC. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: A meta‐analysis.Addiction2015110692093010.1111/add.1287525664494
     [Google Scholar]
  13. JonasD.E. AmickH.R. FeltnerC. BobashevG. ThomasK. WinesR. KimM.M. ShanahanE. GassC.E. RoweC.J. GarbuttJ.C. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis.JAMA2014311181889190010.1001/jama.2014.362824825644
     [Google Scholar]
  14. MannK. LehertP. MorganM.Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis.Alcohol. Clin. Exp. Res.2004281516310.1097/01.ALC.0000108656.81563.0514745302
     [Google Scholar]
  15. RösnerS. Hackl-HerrwerthA. LeuchtS. LehertP. VecchiS. SoykaM. Acamprosate for alcohol dependence.Cochrane Database Syst. Rev.20109CD00433220824837
     [Google Scholar]
  16. AddoloratoG. LeschO.M. MaremmaniI. WalterH. NavaF. RaffaillacQ. CaputoF. Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects.Expert Opin. Drug Saf.202019215916610.1080/14740338.2020.170982131876433
     [Google Scholar]
  17. DauvilliersY. ArnulfI. MignotE. Narcolepsy with cataplexy.Lancet2007369956049951110.1016/S0140‑6736(07)60237‑217292770
     [Google Scholar]
  18. ChickJ. NuttD.J. Substitution therapy for alcoholism: Time for a reappraisal?J. Psychopharmacol.201226220521210.1177/026988111140846321742726
     [Google Scholar]
  19. AddoloratoG. CastelliE. StefaniniG.F. CasellaG. CaputoF. MarsigliL. BernardiM. GasbarrinG. An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects.Alcohol Alcohol.199631434134510.1093/oxfordjournals.alcalc.a0081608879280
     [Google Scholar]
  20. CaputoF. AddoloratoG. StoppoM. FranciniS. VignoliT. LorenziniF. Del ReA. ComaschiC. AndreoneP. TrevisaniF. BernardiM. Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: An open randomised comparative study.Eur. Neuropsychopharmacol.2007171278178910.1016/j.euroneuro.2007.04.00817611081
     [Google Scholar]
  21. GallimbertiL. FerriM. FerraraS.D. FaddaF. GessaG.L. gamma-Hydroxybutyric acid in the treatment of alcohol dependence: A double-blind study.Alcohol. Clin. Exp. Res.199216467367610.1111/j.1530‑0277.1992.tb00658.x1326902
     [Google Scholar]
  22. MarremmaniI. LamannaF. TagliamonteA. Long-term therapy using GHB (sodium gamma hydroxybutyrate) for treatment-resistant chronic alcoholics.J. Psychoactive Drugs200133213514210.1080/02791072.2001.1040047811476260
     [Google Scholar]
  23. SewellR.A. PetrakisI.L. Does gamma-hydroxybutyrate (GHB) have a role in the treatment of alcoholism?Alcohol Alcohol.20114611210.1093/alcalc/agq08621156757
     [Google Scholar]
  24. Van den BrinkW. AddoloratoG. AubinH.J. BenyaminaA. CaputoF. DematteisM. GualA. LeschO.M. MannK. MaremmaniI. NuttD. PailleF. PerneyP. RehmJ. ReynaudM. SimonN. SöderpalmB. SommerW.H. WalterH. SpanagelR. Efficacy and safety of sodium oxybate in alcohol‐dependent patients with a very high drinking risk level.Addict. Biol.201823496998610.1111/adb.1264530043457
     [Google Scholar]
  25. LeoneM.A. Vigna-TagliantiF. AvanziG. BrambillaR. FaggianoF. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses.Cochrane Libr.20102CD00626610.1002/14651858.CD006266.pub220166080
     [Google Scholar]
  26. MonciniM. MasiniE. GambassiF. MannaioniP.F. Gamma-hydroxybutyric acid and alcohol-related syndromes.Alcohol200020328529110.1016/S0741‑8329(99)00093‑210869871
     [Google Scholar]
  27. SchwartzR.H. MilteerR. LeBEAU, M.A. Drug-facilitated sexual assault (‘date rape’).South. Med. J.200093655856110.1097/00007611‑200093060‑0000210881768
     [Google Scholar]
  28. DegenhardtL. DarkeS. DillonP. GHB use among Australians: Characteristics, use patterns and associated harm.Drug Alcohol Depend.2002671899410.1016/S0376‑8716(02)00017‑012062782
     [Google Scholar]
  29. MasonP.E. KernsW.P.II Gamma hydroxybutyric acid (GHB) intoxication.Acad. Emerg. Med.20029773073910.1197/aemj.9.7.73012093716
     [Google Scholar]
  30. DutchM.J. AustinK.B. Hospital in the field: Prehospital management of GHB intoxication by medical assistance teams.Prehosp. Disaster Med.201227546346710.1017/S1049023X1200099422809488
     [Google Scholar]
  31. LiberatiA. AltmanD.G. TetzlaffJ. MulrowC. GøtzscheP.C. IoannidisJ.P.A. ClarkeM. DevereauxP.J. KleijnenJ. MoherD. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.BMJ20093391b270010.1136/bmj.b270019622552
     [Google Scholar]
  32. SterneJ.A.C. SavovićJ. PageM.J. ElbersR.G. BlencoweN.S. BoutronI. CatesC.J. ChengH.Y. CorbettM.S. EldridgeS.M. EmbersonJ.R. HernánM.A. HopewellS. HróbjartssonA. JunqueiraD.R. JüniP. KirkhamJ.J. LassersonT. LiT. McAleenanA. ReevesB.C. ShepperdS. ShrierI. StewartL.A. TillingK. WhiteI.R. WhitingP.F. HigginsJ.P.T. RoB 2: A revised tool for assessing risk of bias in randomised trials.BMJ2019366l489810.1136/bmj.l489831462531
     [Google Scholar]
  33. SpiniA. CicconeV. RoselliniP. ZicheM. LucenteforteE. SalvoF. DonniniS. Safety of anti-angiogenic drugs in pediatric patients with solid tumors: A systematic review and meta-analysis.Cancers20221421531510.3390/cancers1421531536358734
     [Google Scholar]
  34. SterneJ.A.C. HernánM.A. ReevesB.C. SavovićJ. BerkmanN.D. ViswanathanM. HenryD. AltmanD.G. AnsariM.T. BoutronI. CarpenterJ.R. ChanA.W. ChurchillR. DeeksJ.J. HróbjartssonA. KirkhamJ. JüniP. LokeY.K. PigottT.D. RamsayC.R. RegidorD. RothsteinH.R. SandhuL. SantaguidaP.L. SchünemannH.J. SheaB. ShrierI. TugwellP. TurnerL. ValentineJ.C. WaddingtonH. WatersE. WellsG.A. WhitingP.F. HigginsJ.P.T. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions.BMJ2016355i491910.1136/bmj.i491927733354
     [Google Scholar]
  35. StellaL. AddoloratoG. RinaldiB. CapuanoA. BerrinoL. RossiF. MaioneS. An open randomized study of the treatment of escitalopram alone and combined with γ-hydroxybutyric acid and naltrexone in alcoholic patients.Pharmacol. Res.200857431231710.1016/j.phrs.2008.03.00118434189
     [Google Scholar]
  36. CaputoF. FranciniS. BrambillaR. Vigna-TagliantiF. StoppoM. Del ReA. LeggioL. AddoloratoG. ZoliG. BernardiM. Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity.Eur. Neuropsychopharmacol.201121645045610.1016/j.euroneuro.2010.12.00521276717
     [Google Scholar]
  37. MaremmaniA.G.I. PaniP.P. RovaiL. PaciniM. Dell’OssoL. MaremmaniI. Long-term γ-hydroxybutyric acid (GHB) and disulfiram combination therapy in GHB treatment-resistant chronic alcoholics.Int. J. Environ. Res. Public Health2011872816282710.3390/ijerph807281621845160
     [Google Scholar]
  38. AddoloratoG. CibinM. CaputoF. CapristoE. GessaG.L. StefaniniG.F. GasbarriniG. γ-Hydroxybutyric acid in the treatment of alcoholism: Dosage fractioning utility in non-responder alcoholic patients.Drug Alcohol Depend.199853171010.1016/S0376‑8716(98)00094‑510933335
     [Google Scholar]
  39. NavaF. PremiS. ManzatoE. LucchiniA. Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptionst.J. Psychoactive Drugs200638321121710.1080/02791072.2006.1039984617165363
     [Google Scholar]
  40. GuiraudJ. AddoloratoG. AubinH.J. BatelP. de BejczyA. CaputoF. GoudriaanA.E. GualA. LeschO. MaremmaniI. PerneyP. PoulnaisR. RaffaillacQ. SoderpalmB. SpanagelR. WalterH. van den BrinkW. Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study.Eur. Neuropsychopharmacol.202152183010.1016/j.euroneuro.2021.06.00334237655
     [Google Scholar]
  41. GuiraudJ. AddoloratoG. AntonelliM. AubinH.J. de BejczyA. BenyaminaA. CacciagliaR. CaputoF. DematteisM. FerrulliA. GoudriaanA.E. GualA. LeschO.M. MaremmaniI. MirijelloA. NuttD.J. PailleF. PerneyP. PoulnaisR. RaffaillacQ. RehmJ. RollandB. RotondoC. ScherrerB. SimonN. SkalaK. SöderpalmB. SomainiL. SommerW.H. SpanagelR. VassalloG.A. WalterH. van den BrinkW. Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial.J. Psychopharmacol.202236101136114510.1177/0269881122110406335796481
     [Google Scholar]
  42. CaputoF. AddoloratoG. LorenziniF. DomenicaliM. GrecoG. del RE, A.; Gasbarrini, G.; Stefanini, G.F.; Bernardi, M. Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: An open randomized comparative study.Drug Alcohol Depend.2003701859110.1016/S0376‑8716(02)00340‑X12681528
     [Google Scholar]
  43. McGuinnessL.A. HigginsJ.P.T. Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessments.Res. Synth. Methods2021121556110.1002/jrsm.141132336025
     [Google Scholar]
  44. O’MalleyS.S. JaffeA.J. ChangG. SchottenfeldR.S. MeyerR.E. RounsavilleB. Naltrexone and coping skills therapy for alcohol dependence. A controlled study.Arch. Gen. Psychiatry1992491188188710.1001/archpsyc.1992.018201100450071444726
     [Google Scholar]
  45. GuiraudJ. AddoloratoG. AubinH.J. BachelotS. BatelP. de BejczyA. BenyaminaA. CaputoF. CoudercM. DematteisM. GoudriaanA.E. GualA. LecousteyS. LeschO.M. MaremmaniI. NuttD.J. PailleF. PerneyP. RehmJ. RollandB. ScherrerB. SimonN. SöderpalmB. SomainiL. SommerW.H. SpanagelR. WalterH. van den BrinkW. Sodium oxybate for alcohol dependence: A network meta-regression analysis considering population severity at baseline and treatment duration.Alcohol Alcohol.202358212513310.1093/alcalc/agac07036617267
     [Google Scholar]
  46. CaputoF. Del ReA. BrambillaR. GrignaschiA. VignoliT. Vigna-TagliantiF. AddoloratoG. ZoliG. CibinM. BernardiM. Sodium oxybate in maintaining alcohol abstinence in alcoholic patients according to Lesch typologies: A pilot study.J. Psychopharmacol.2014281233010.1177/026988111350401524045881
     [Google Scholar]
  47. ScherrerB. GuiraudJ. AddoloratoG. AubinH.J. de BejczyA. BenyaminaA. van den BrinkW. CaputoF. DematteisM. GoudriaanA.E. GualA. KieferF. LeggioL. LeschO.M. MaremmaniI. NuttD.J. PailleF. PerneyP. PoulnaisR. RaffaillacQ. RehmJ. RollandB. SimonN. SöderpalmB. SommerW.H. WalterH. SpanagelR. Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A meta‐regression analysis to develop an enrichment strategy.Alcohol. Clin. Exp. Res.20214591722173410.1111/acer.1467034418121
     [Google Scholar]
  48. GueorguievaR. WuR. DonovanD. RounsavilleB.J. CouperD. KrystalJ.H. O’MalleyS.S. Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE study: Empirically derived predictors of drinking outcomes during treatment.Alcohol201246212113110.1016/j.alcohol.2011.08.00821925828
     [Google Scholar]
  49. DarraghM. BoothR.J. ConsedineN.S. Investigating the ‘placebo personality’ outside the pain paradigm.J. Psychosom. Res.201476541442110.1016/j.jpsychores.2014.02.01124745784
     [Google Scholar]
  50. BeissnerF. BrünnerF. FinkM. MeissnerK. KaptchukT.J. NapadowV. Placebo-induced somatic sensations: A multi-modal study of three different placebo interventions.PLoS One2015104e012480810.1371/journal.pone.012480825901350
     [Google Scholar]
  51. HakulinenC. ElovainioM. Pulkki-RåbackL. VirtanenM. KivimäkiM. JokelaM. Personality and depressive symptoms: Individual participant meta-analysis of 10 cohort studies.Depress. Anxiety201532746147010.1002/da.2237626014798
     [Google Scholar]
  52. DeanS.F. FedeS.J. DiazgranadosN. MomenanR. Addiction neurocircuitry and negative affect: A role for neuroticism in understanding amygdala connectivity and alcohol use disorder.Neurosci. Lett.202072213477310.1016/j.neulet.2020.13477332045624
     [Google Scholar]
  53. PallucchiniA. CarliM. MaremmaniA. ScarselliM. PerugiG. MaremmaniI. Influence of substance use disorder on treatment retention of adult-attention-deficit/hyperactive disorder patients. A 5-year follow-up study.J. Clin. Med.2021109198410.3390/jcm1009198434063121
     [Google Scholar]
  54. AddoloratoG. CaputoF. CapristoE. DomenicaliM. BernardiM. JaniriL. AgabioR. ColomboG. GessaG.L. GasbarriniG. Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study.Alcohol Alcohol.200237550450810.1093/alcalc/37.5.50412217947
     [Google Scholar]
  55. GolkaK. WieseA. Carbohydrate-deficient transferrin (CDT)--a biomarker for long-term alcohol consumption.J. Toxicol. Environ. Health B Crit. Rev.20047431933710.1080/1093740049043240015205047
     [Google Scholar]
  56. HelanderA. PéterO. ZhengY. Monitoring of the alcohol biomarkers PEth, CDT and EtG/EtS in an outpatient treatment setting.Alcohol Alcohol.201247555255710.1093/alcalc/ags06522691387
     [Google Scholar]
  57. SuzukiT. EguchiA. ShigefukuR. NagaoS. MorikawaM. SugimotoK. IwasaM. TakeiY. Accuracy of carbohydrate‐deficient transferrin as a biomarker of chronic alcohol abuse during treatment for alcoholism.Hepatol. Res.202252112012710.1111/hepr.1364233797850
     [Google Scholar]
  58. AntonelliM. SestitoL. TarliC. AddoloratoG. Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?Eur. J. Intern. Med.2022103132210.1016/j.ejim.2022.05.01635597734
     [Google Scholar]
  59. WangY.G. SwickT.J. CarterL.P. ThorpyM.J. BenowitzN.L. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): Abuse, misuse, dependence, and diversion.J. Clin. Sleep Med.200954365371
     [Google Scholar]
  60. DrakatosP. LykourasD. D’AnconaG. HigginsS. GildehN. MacaveiR. RosenzweigI. SteierJ. WilliamsA.J. MuzaR. KentB.D. LeschzinerG. Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice.Sleep Med.201735808410.1016/j.sleep.2017.03.02828619187
     [Google Scholar]
  61. ChenC. JenkinsJ. ZomorodiK. SkowronskiR. Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies.Clin. Transl. Sci.20211462278228710.1111/cts.1308734121333
     [Google Scholar]
  62. KothareS V. KaleyiasJ. Pharmacotherapy of narcolepsy: Focus on sodium oxybate.Clin. Med. Insights Ther.20102cmt.s1087
     [Google Scholar]
  63. KernA. KrammC. WittC.M. BarthJ. The influence of personality traits on the placebo/nocebo response.J. Psychosom. Res.202012810986610.1016/j.jpsychores.2019.10986631760341
     [Google Scholar]
  64. LuchettiM. SutinA.R. DelitalaA. StephanY. FiorilloE. MarongiuM. MasalaM. SchlessingerD. TerraccianoA. Personality traits and facets linked with self-reported alcohol consumption and biomarkers of liver health.Addict. Behav.20188213514110.1016/j.addbeh.2018.02.03429525559
     [Google Scholar]
  65. NietoS.J. GrodinE.N. BurnetteE.M. CahillC.M. RayL.A. Pain catastrophizing is associated with increased alcohol cue-elicited neural activity among individuals with alcohol use disorder.Alcohol Alcohol.2022576agac02910.1093/alcalc/agac02935788255
     [Google Scholar]
  66. StanglB.L. SchusterR.M. SchneiderA. DechertA. PotterK.W. HareliM. MahmudF. YalinE.R. RamchandaniV.A. GilmanJ.M. Suggestibility is associated with alcohol self-administration, subjective alcohol effects, and self-reported drinking behavior.J. Psychopharmacol.201933776977810.1177/026988111982781330829118
     [Google Scholar]
  67. CaputoF. VignoliT. TarliC. DomenicaliM. ZoliG. BernardiM. AddoloratoG. A brief up-date of the use of sodium oxybate for the treatment of alcohol use disorder.Int. J. Environ. Res. Public Health201613329010.3390/ijerph1303029026959045
     [Google Scholar]
  68. CraigK. GomezH.F. McManusJ.L. BaniaT.C. Severe gamma-hydroxybutyrate withdrawal: A case report and literature review.J. Emerg. Med.2000181657010.1016/S0736‑4679(99)00163‑810645841
     [Google Scholar]
  69. Ceylan-IsikA.F. McBrideS.M. RenJ. Sex difference in alcoholism: Who is at a greater risk for development of alcoholic complication?Life Sci.2010875-613313810.1016/j.lfs.2010.06.00220598716
     [Google Scholar]
  70. TuckerJ. ChandlerS.D. WitkiewitzK. Epidemiology of recovery from alcohol use disorder.Alcohol Res.20204030210.35946/arcr.v40.3.0233194507
     [Google Scholar]
  71. GohC.M.J. AsharaniP.V. AbdinE. ShahwanS. ZhangY. SambasivamR. Gender differences in alcohol use: A nationwide study in a multiethnic population.Int. J. Ment. Health Addict.2024221161117510.1007/s11469‑022‑00921‑y
     [Google Scholar]
/content/journals/cn/10.2174/1570159X22666240902100058
Loading
Long-term Efficacy and Safety of Sodium Oxybate in Treating Alcohol Use Disorder: A Systematic Review and Meta-Analysis
Curr. Neuropharmacol. 23, 579 (2025); https://doi.org/10.2174/1570159X22666240902100058
/content/journals/cn/10.2174/1570159X22666240902100058
/content/journals/cn/10.2174/1570159X22666240902100058
Loading

Data & Media loading...

Supplements

PRISMA checklist and supplementary material are available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): abstinence; alcohol use disorder; craving; efficacy; long-term treatment; safety; Sodium oxybate

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test